Even though the involvement of mTOR and AhR signaling pathways in the development of chronic kidney diseases has been well-established (Swaroop et al., 2024; Zhao et al., 2019), the potential of α-MT as a modulator of these pathways in the treatment of DN has not been investigated. The gene discussed is AHR; the disease is chronic kidney disease.